Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2020 pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Development of a hepatic fibrosis biomarker using Magnetic Resonance Elastography (MRE) and Magnetic Resonance Imaging (MRI)
An AI-based biomarker potentially presenting better performance than existing imaging biomarkers.
Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2020, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
• Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m)
• Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019
• Order backlog of €50.7m
• Cash and cash equivalents of €17.3m
To download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]